Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $32.6667.

Several research analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, October 6th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 target price on the stock. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Wells Fargo & Company initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 target price on the stock. Finally, Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday. They set an “overweight” rating and a $35.00 target price on the stock.

Centessa Pharmaceuticals Stock Up 2.2%

NASDAQ:CNTA opened at $25.00 on Friday. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -13.97 and a beta of 1.57. Centessa Pharmaceuticals has a twelve month low of $9.60 and a twelve month high of $25.31. The stock’s 50 day moving average price is $21.24 and its two-hundred day moving average price is $16.49. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CTO Tia L. Bush sold 35,000 shares of the business’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $24.00, for a total value of $840,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares in the company, valued at $2,916,072. The trade was a 22.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Iqbal J. Hussain sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total value of $400,200.00. Following the completion of the sale, the general counsel owned 105,386 shares of the company’s stock, valued at $2,108,773.86. This trade represents a 15.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 145,964 shares of company stock valued at $3,169,861. 7.09% of the stock is owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after purchasing an additional 870 shares during the period. HighMark Wealth Management LLC boosted its stake in Centessa Pharmaceuticals by 0.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock valued at $3,118,000 after purchasing an additional 1,500 shares during the period. HighVista Strategies LLC boosted its stake in Centessa Pharmaceuticals by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock valued at $535,000 after purchasing an additional 1,664 shares during the period. Trexquant Investment LP boosted its stake in Centessa Pharmaceuticals by 1.1% in the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock valued at $3,796,000 after purchasing an additional 2,810 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after purchasing an additional 3,194 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.